Cantargia AB (CANTA)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 1.374 |
|---|---|
| 52-week range | 1.250 – 6.590 |
| Return, 1 month / 3 months | −5.9% / −26.7% |
| Return, 1 year / 3 years | −54.8% / −61.3% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 74.5% |
| Worst drawdown (1 year) | -79.3% |
| Average daily value traded | 2.17M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cantargia AB is a biotechnology company based in Lund, Sweden, that develops antibody-based treatments for cancer. Its work centres on therapies that target a protein found on certain cancer cells and on the cells supporting tumours, aiming to help the body's immune system attack the disease. The company carries out research and clinical development of these drug candidates, working with partners and investigators in the oncology field.
Cantargia AB trades under the code CANTA on the Nasdaq Stockholm in Sweden, with its price quoted in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cantargia AB (CANTA) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 1.374 on 27 October 2026.
Its price-based Market X-Ray is 21 out of 100 (a weak price profile), ranking 784 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 54.8% and over the last three months it fell 26.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 6 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -53.7% | ||
| From 52-week high | -77.8% | ||
| Momentum | 11 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -26.7% | ||
| 6-month return | -64.5% | ||
| 12-month return, skipping the last month | -52.0% | ||
| Stability (higher is calmer) | 20 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 74.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -79.3% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.17M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.5% |
|---|---|
| 1 month | −5.9% |
| 3 months | −26.7% |
| 6 months | −64.5% |
| 1 year | −54.8% |
| 3 years | −61.3% |
| 5 years | −90.0% |
Signals
| 50-day / 200-day average | 1.563 / 2.969 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.080 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.